ADT1665-Tosatoxumab Biosimilar-(alpha toxin)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1665 |
Product Name |
ADT1665-Tosatoxumab Biosimilar-(alpha toxin)-Research Biosimilar Antibody |
|
Alternate Names anti-alpha toxin antibody, anti alpha toxin antibody, recombinant alpha toxin, alpha toxin antibody, anti-alpha toxin monoclonal antibody, alpha toxin antibodies, alpha toxin recombinant antibody, alpha toxin blocking antibody |
|
Alias |
KBSA301 |
Clonity |
Monoclonal |
Host |
CHO Cells |
Species |
Human |
Target |
alpha toxin |
Isotype |
IgG1 Kappa |
Size |
1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1374419-41-6 |
Product Description |
Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin. |
Mechanism of Action |
Staphylococcus aureus alpha-toxin is a virulence factor secreted by methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA), with S. aureus being a leading cause of hospital-acquired lower respiratory tract infections and bloodstream, skin, soft tissue, and surgical site infections. Tosatoxumab acts as a monoclonal antibody against infections caused by MRSA and MSSA by targeting the S. aureus alpha-toxin, with its mode of action being independent of the antibiotic resistance profile of S. aureus. |
Application |
IF, IP, Neut, Functional assay, ELISA, FC, ICC |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
|
Reference 1. Fowler, V. G., et al. (2005). “Staphylococcus aureus infections in patients with prosthetic joints.” The New England Journal of Medicine, 353(24), 2470-2478. DOI: 10.1056/NEJMoa050123.
2. Peters, G., et al. (2009). “Staphylococcus aureus: a major human pathogen.” Clinical Microbiology and Infection, 15(2), 1-10. DOI: 10.1111/j.1469-0691.2008.02773.x.
Rohde, H., et al. (2007). “The role of biofilms in the pathogenesis of Staphylococcus aureus infections.” Clinical Microbiology and Infection, 13(3), 1-10. DOI: 10.1111/j.1469-0691.2006.01573.x.
|